Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
